Continuous glucose monitors and insulin pumps have revolutionized diabetes care for millions of patients, but a series of major recalls over the past two years has heightened concerns about the safety and reliability of these critical medical devices.

The most significant recent recall involved Abbott’s FreeStyle Libre 3 glucose sensors in October 2023. Abbott Diabetes Care recalled certain FreeStyle Libre 3 sensors due to incorrect glucose readings that displayed lower values than actual blood glucose levels. According to FDA documents, these inaccurate readings could lead to wrong treatment decisions, including excessive carbohydrate intake or delayed insulin doses, potentially causing serious health complications.

The FDA classified this as a Class I recall, its most serious designation reserved for devices that could cause serious injury or death. Abbott reported that approximately 3.3 million sensors distributed in the United States were potentially affected by the manufacturing defect, making it one of the largest diabetes device recalls in recent years.

“If undetected, these incorrect glucose readings over an extended period may lead to wrong treatment decisions for people living with diabetes,” Abbott stated in its recall notice. “These decisions may pose serious health risks, including potential injury or death.”

This recall followed other significant diabetes device safety issues in recent years. In 2022, Tandem Diabetes Care issued a recall for certain t:slim X2 insulin pumps due to a cartridge fill issue that could result in under-delivery of insulin. The company warned that cartridges might not fill completely, potentially leading to hyperglycemia if users didn’t notice the problem.

Medtronic has also faced multiple recalls of its MiniMed insulin pumps. In 2021, the company recalled certain MiniMed 600 and 700 series pumps due to missing or broken retainer rings that could cause the reservoir to crack, leak, or become loose, potentially leading to under-delivery or over-delivery of insulin.

These recalls have exposed vulnerabilities in devices that an estimated 350,000 to 400,000 Americans depend on daily, according to data from the American Diabetes Association. For the approximately 1.9 million Americans with Type 1 diabetes, these devices can be life-saving technology.

“Insulin pumps help play the role of the pancreas by releasing insulin,” according to Cleveland Clinic medical information. However, malfunctions that result in too much or too little insulin delivery can lead to dangerous blood sugar swings.

The pattern of recalls raises questions about manufacturing quality control and device testing protocols. Many of the affected devices represent advanced diabetes management technology, including automated insulin delivery systems that adjust insulin doses based on continuous glucose readings from paired sensors.

Dr. Anne Peters, a diabetes specialist at USC’s Keck School of Medicine, has noted in published interviews that while these devices have dramatically improved diabetes management, “we need to ensure that the technology is reliable and safe for the people who depend on it every day.”

The recalls have also highlighted challenges in how patients and healthcare providers are notified about device problems. The FDA has acknowledged that communication about recalls can be improved, particularly for devices that patients use continuously.

In response to these concerns, the FDA has expanded its Communications Pilot Program, which aims to improve the timeliness and effectiveness of recall communications. According to the FDA’s Center for Devices and Radiological Health, the expanded program “aims to improve the timeliness of communications about corrective actions being taken by companies.”

Patient advocacy groups have called for better recall notification systems and more robust post-market surveillance of diabetes devices. The Juvenile Diabetes Research Foundation has emphasized the need for manufacturers to prioritize safety and quality control, given the critical nature of these devices for patient health.

Industry observers note that while recalls highlight serious safety concerns, they also demonstrate that monitoring systems are identifying problems. However, the concentration of high-profile recalls in the diabetes device sector suggests manufacturers may need to strengthen quality assurance measures.

The recalls come as diabetes management technology continues to evolve rapidly, with new features like smartphone connectivity and increasingly sophisticated automated dosing algorithms. As devices become more complex, ensuring their reliability becomes even more critical.

For patients using diabetes devices, manufacturers and healthcare providers recommend regularly checking for recall notices, keeping device software updated, and maintaining backup blood glucose testing supplies. The FDA advises patients to never ignore unusual device behavior and to contact their healthcare provider immediately if they suspect a device malfunction.

Healthcare providers are being encouraged to counsel patients on recognizing signs of device problems, including unexpected blood glucose patterns, device error messages, or physical damage to sensors or pumps.

As diabetes technology continues advancing, the recent recalls serve as important reminders that rigorous safety standards and quality control measures must keep pace with innovation to protect the millions of Americans who rely on these devices for daily diabetes management.